Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doramapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 10/20 | 0.98 |
| ▸ | TNF | P01375 | 7/20 | 0.98 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.98 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.98 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.98 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | MUSK | O15146 | 1/20 | 0.98 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | RAF1 | P04049 | 1/20 | 0.98 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.98 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.98 |
| ▸ | PRKCB | P05771 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doramapimod SCHEMBL29353023 | 0.99 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| Doramapimod SCHEMBL129721 | 0.99 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL20876996 | 0.95 | MAPK14 (0.93) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL14185084 | 0.95 | MAPK14 (0.91) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6330722 | 0.95 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295302 | 0.94 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5967533 | 0.93 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL13857350 | 0.93 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295792 | 0.93 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL29594033 | 0.93 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484661-B1 | 2,3-DIHYDRO-1H-INDENE-2-YLUREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME | TORAY INDUSTRIES (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8653304-B2 | 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same | TORAY INDUSTRIES, INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2484661-A1 | 2,3-DIHYDRO-1H-INDENE-2-YLUREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME | Toray Industries, Inc. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184735-A1 | 2,3-DIHYDRO-1H-INDENE-2-YL UREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME | TORAY INDUSTRIES, INC. (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184735-A1 | 2,3-DIHYDRO-1H-INDENE-2-YL UREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME | SLC14A1, UROD, UGP2 | MAPK14 2082/4885TNF 4156/4885MAPK13 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.